FDA Grants Priority Review to Rituxan Plus Glucocorticoids for Children with GPA and MPA
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Rituxan (rituximab) in combination with glucocorticoids for the treatment of children, 2 or older, with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). If Genentech‘s Biologics License Application (sBLA) for Rituxan is approved, this…